3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Sarcoma
26
Glioblastoma
25
Gliosarcoma
22
Rhabdomyosarcoma
21
Sarcoma, Ewing
18
Glioma
15
Brain Neoplasms
14
Astrocytoma
13
Neuroblastoma
12
Central Nervous System Neoplasms
12
Oligodendroglioma
9
Osteosarcoma
8
Neoplasms
7
Medulloblastoma
6
Pancreatic Neoplasms
5
Neuroectodermal Tumors, Primitive, Peripheral
5
Neoplasm Metastasis
5
Breast Neoplasms
5
Colorectal Neoplasms
4
Bone Neoplasms
4
Stomach Neoplasms
3
Recurrence
3
Optic Nerve Glioma
3
Malignant mesenchymal tumor
3
Diffuse Intrinsic Pontine Glioma
3
Colonic Neoplasms
3
Wilms Tumor
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Rhabdoid Tumor
2
Interventions
Standard of Care
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Transurethral Resection of Bladder
1
STA 9090
1
SGN-LIV1A
1
Paclitaxel
1
MK 2206
1
Letrozole
1
Lasofoxifene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Irinotecan
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled